Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
Accenture
Fuji
Moodys
Federal Trade Commission

Generated: September 16, 2019

DrugPatentWatch Database Preview

Patent: 9,693,987

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,693,987
Title:Methods for treating cancers using oral formulations of cytidine analogs
Abstract: Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.
Inventor(s): MacBeth; Kyle J. (San Francisco, CA), Nguyen; Aaron N. (San Jose, CA), Dimartino; Jorge (Belmont, CA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:14/688,623
Patent Claims:see list of patent claims

Details for Patent 9,693,987

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Celgene Corporation (Summit, NJ) 2031-11-01 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Celgene Corporation (Summit, NJ) 2031-11-01 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Try a Free Trial Celgene Corporation (Summit, NJ) 2031-11-01 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Try a Free Trial Celgene Corporation (Summit, NJ) 2031-11-01 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Try a Free Trial Celgene Corporation (Summit, NJ) 2031-11-01 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial Celgene Corporation (Summit, NJ) 2031-11-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Federal Trade Commission
Colorcon
US Department of Justice
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.